Jeremy Force

Duke University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Purpose: Activating mutations in AKT genes are rare but play an important role in the commonly dysregulated PI3K/AKT/mTOR signaling pathway in multiple cancers. NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolled patients to targeted therapies based on matching tumor genomic alterations. Subprotocol Z1K evaluated ipatasertib, a pan-AKT inhibitor, in patients with AKT1 E17K -mutant metastatic tumors. Patients and Methods: Patients received ipatasertib 400 mg orally once daily in a 28-day cycle until progression or unacceptable toxicity. Patients with well-controlled diabetes were eligible. Patients with known KRAS , NRAS , HRAS , or BRAF mutations were excluded. Prior PI3K and mTOR inhibitors were allowed. Prior AKT inhibitors were excluded. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival, 6-month progression-free survival, and toxicity. Results: Thirty-five patients were enrolled, and 29 patients were included in the prespecified primary efficacy analysis. Multiple histologies were enrolled, with breast ( n = 18) and gynecologic ( n = 7) being the most common. The majority had >3 lines of prior therapy (19/29; 65.5%). The ORR was 24.1% (7/29; 90% confidence interval, 11.9%–40.6%) with P n = 25), nausea ( n = 13), and hyperglycemia ( n = 9). Grade 3/4 toxicities observed were consistent with reported toxicities for AKT inhibition. Twelve grade 3 events occurred that were thought to be at least possibly related to treatment. Conclusions: The study met its primary endpoint with an ORR of 24.1% ( P AKT1 E17K mutations. See related commentary by Dahmer Tiecher and Schram, p. 4863

Year:

2025

Year:

2023

Year:

2021

Collaborators (6)

Lawrence Rubinstein

Statistician

National Cancer Institute

UNITED STATES
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES
View details

Kevin Kalinsky

Emory University

UNITED STATES
View details

Carlos L. Arteaga

University of Texas Southwestern Medical Center

UNITED STATES
View details